|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Paclitaxel and Carboplatin Versus No Adjuvant Chemotherapy After Resection in Patients With Stage IB Non-Small Cell Lung Cancer
Special Category: CTSU trial Trial Description Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether surgery is more effective with or without chemotherapy for non-small cell lung cancer. Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned to one of two groups. Patients in group one will receive no further therapy following surgery. Patients in group two will receive infusions of carboplatin and paclitaxel every 3 weeks for four courses. Patients will receive follow-up examinations every 4 months for 2 years and every 6 months thereafter. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Cancer and Leukemia Group B
Radiation Therapy Oncology Group
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |